Isoniazid (INH) targets Mycobacterium tuberculosis by inhibiting mycolic acid synthesis, a crucial component of the bacterial cell wall. This interference disrupts bacterial growth and ultimately leads to cell death. However, INH requires activation through a process involving the bacterial enzyme KatG. This activation process is critical for its antibacterial effect.
INH’s Impact on Pyridoxine
INH’s mechanism also involves interaction with pyridoxine (vitamin B6), leading to its depletion. INH competes with pyridoxine for aldehyde oxidase, an enzyme involved in pyridoxine metabolism. This competition reduces the availability of pyridoxal 5′-phosphate (PLP), the active form of pyridoxine, a coenzyme necessary for various metabolic processes, including amino acid metabolism and neurotransmitter synthesis. Insufficient PLP can cause peripheral neuropathy, a common side effect of INH treatment.
Recommended Pyridoxine Supplementation
To mitigate pyridoxine depletion during INH treatment, supplemental pyridoxine is often prescribed. The recommended dose varies depending on factors such as patient age, health status, and INH dosage. Always consult a healthcare professional to determine the appropriate pyridoxine dosage for your specific situation. This preventative measure helps minimize the risk of INH-induced peripheral neuropathy and other adverse effects related to pyridoxine deficiency.
